Filed Pursuant to Rule 424(b)(5)
Registration No. 333-275138
This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
Subject to Completion,
Dated March 25, 2024
Preliminary Prospectus Supplement
(To Prospectus dated October 23, 2023)
$840,000,000
Shares of Common Stock
We expect to enter into a forward sale agreement with Bank of America, N.A. which we refer to in this capacity as the forward purchaser. In connection with the forward sale agreement, we expect that the forward purchaser or its affiliate will borrow from third parties and sell to the underwriter $840,000,000 of shares of our common stock, $0.01 par value per share, that will be delivered in this offering. The underwriter expects to sell all of the shares of common stock to an existing long-only investor based on the West Coast, at a price per share equal to the closing price of our common stock on the New York Stock Exchange, or NYSE, on March 26, 2024. See “Underwriting.” Because this investor’s indication of interest is not a binding agreement or commitment to purchase, this investor could determine to purchase more, less or no shares in this offering or the underwriter could determine to sell more, less or no shares to this investor.
We will not receive any proceeds from the sale of shares of our common stock offered by the forward purchaser or its affiliate. We expect to physically settle the forward sale agreement (by the delivery of shares of our common stock) and receive proceeds from the sale of those shares of our common stock upon one or more forward settlement dates within approximately 18 months from the date hereof. We may also elect to cash settle or net share settle all or a portion of our obligations under the forward sale agreement (if we conclude that it is in our best interest to do so). If we elect to cash settle the forward sale agreement, we may not receive any proceeds, and we may owe cash to the forward purchaser in certain circumstances. If we elect to net share settle the forward sale agreement, we will not receive any proceeds, and we may owe shares of our common stock to the forward purchaser in certain circumstances. See “Underwriting—Forward Sale Agreement.”
If the forward purchaser or its affiliate does not deliver and sell all of the shares of our common stock to be delivered and sold by it pursuant to the terms of the underwriting agreement, we will issue and sell directly to the underwriter the number of shares of our common stock not delivered and sold by the forward purchaser or its affiliate, and the number of shares of our common stock underlying the forward sale agreement will be decreased by the number of shares of our common stock that we issue and sell.
We are organized and conduct our operations to qualify as a real estate investment trust, or REIT, for federal income tax purposes. To assist us in complying with certain federal income tax requirements applicable to REITs, our charter contains certain restrictions relating to the ownership and transfer of our capital stock, including an ownership limit of 9.8% of the outstanding shares of our common stock.
Concurrently with this offering, Rexford Industrial Realty, L.P., which we refer to as our operating partnership, is offering % exchangeable senior notes due 2027, which we refer to as the 2027 exchangeable notes, in an aggregate principal amount of $500,000,000 and % exchangeable senior notes due 2029, which we refer to as the 2029 exchangeable notes, and together with the 2027 exchangeable notes, the exchangeable notes, in an aggregate principal amount of $500,000,000, plus up to an additional $75,000,000 aggregate principal amount of 2027 exchangeable notes and up to an additional $75,000,000 aggregate principal amount of 2029 exchangeable notes that the initial purchasers of the concurrent offering have the option to purchase from our operating partnership. The concurrent offering is being made pursuant to a confidential offering memorandum (and not pursuant to this prospectus supplement or the accompanying prospectus) only to qualified institutional buyers (as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”)) in transactions that are exempt from the registration and prospectus-delivery requirements of the Securities Act. The completion of this offering is not contingent on the completion of the concurrent offering, and the completion of the concurrent offering is not contingent on the completion of this offering. This prospectus supplement and the accompanying prospectus do not constitute an offer to sell, or the solicitation of an offer to buy, any of the exchangeable notes, or the shares of common stock, if any, deliverable upon exchange of the exchangeable notes, that our operating partnership is offering in the concurrent offering. See “The Concurrent Offering.”
Our common stock is listed on the New York Stock Exchange, or NYSE, under the symbol “REXR,” and the last reported sale price of our common stock on the NYSE on March 22, 2024 was $50.92 per share.
Investing in our common stock involves risks. See “Risk Factors” beginning on page S-7 of this prospectus supplement and the risks set forth under the caption “Item 1A. Risk Factors” included in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, and as updated by our subsequent Quarterly Reports on Form 10-Q as well as any of our other subsequent filings under the Exchange Act, which are incorporated by reference herein, for certain risks relevant to an investment in our common stock.
| | | | | | | | |
| | Per Share | | | Total | |
Public offering price | | $ | | | | $ | | |
Underwriting discounts and commissions(1) | | $ | | | | $ | | |
Proceeds, before expenses, to us(2) | | $ | | | | $ | | |
(1) | See “Underwriting” for a description of all compensation payable to the underwriter. |
(2) | We expect to receive approximately $ million of aggregate net proceeds before expenses from this offering upon full physical settlement of the forward sale agreement, assuming an initial forward sale price of $ per share. The forward sale price is subject to adjustment pursuant to the forward sale agreement, and the actual proceeds, if any, will be calculated pursuant to the forward sale agreement. We may also elect to cash settle or net share settle all or a portion of our obligations under the forward sale agreement. See “Underwriting—Forward Sale Agreement.” |
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement and the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The underwriter expects to deliver the shares to the purchaser on or about , 2024 through the book-entry facilities of The Depository Trust Company.
Sole Book-Running Manager
BofA Securities
The date of this prospectus supplement is , 2024